24,266 results match your criteria Chronic Myelogenous Leukemia


Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine.

Clin Cancer Res 2020 Jul 6. Epub 2020 Jul 6.

Comprehensive Cancer Center, St. Jude Children's Research Hospital

Purpose: Rhabdoid tumors (RTs) are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of RT.

Experimental Design: We screened eight RT cell lines with 481 small molecules and compared their sensitivity to that of 879 other cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-2717DOI Listing

[Progress of MM/CML treatment and medical economics].

Authors:
Kenshi Suzuki

Rinsho Ketsueki 2020 ;61(6):587-597

Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center.

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors (TKIs) is an important issue in chronic myelogenous leukemia (CML). Similarly, although overall survival (OS) has tremendously improved, the treatment of multiple myeloma (MM), including 12 new drugs, typically costs more than $100,000 per year. This price should not be judged in isolation but rather evaluated in the context of clinical benefit, which can be assessed by cost-effectiveness analyses such as the total cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.587DOI Listing
January 2020

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.

Haematologica 2020 Jul 2. Epub 2020 Jul 2.

Department of Physiology, Radboud University Medical Center, Nijmegen, The Netherlands;

Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. However, the prevalence of TKI-induced fatigue remains uncertain and little is known about predictors of fatigue and its relationship with physical activity. In this study, 220 CML patients receiving TKI therapy and 110 gender- and age-matched controls completed an online questionnaire to assess fatigue severity and fatigue predictors (Part 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.247767DOI Listing

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia: A Case Report.

Intern Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Japan.

Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4824-20DOI Listing

Periodic hematological disorders: Quintessential examples of dynamical diseases.

Authors:
Michael C Mackey

Chaos 2020 Jun;30(6):063123

Department of Physiology, Department of Physics, and Department of Mathematics McGill University, Montreal, Quebec H4X 2C1, Canada.

This paper summarizes the evidence supporting the classification of cyclic neutropenia as a dynamical disease and periodic chronic myelogenous leukemia is also considered. The unsatisfactory state of knowledge concerning the genesis of cyclic thrombocytopenia and periodic autoimmune hemolytic anemia is detailed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/5.0006517DOI Listing

Expression of Ki-67 and CD34 on blood and bone marrow cells of CML patients with different response to imatinib and nilotinib therapy.

Exp Oncol 2020 06;42(2):144-147

State Institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine", Kyiv 004050, Ukraine.

Aim: To assess the expression of Ki-67 protein and CD34 antigen on peripheral blood (PB) and bone marrow (BM) cells in chronic myelogenous leukemia (CML) patients with different response to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) therapy.

Patients And Methods: BM aspirate and PB samples from 41 CML patients treated with IM and NI were studied by cytogenetic, molecular genetic, and flow cytometry methods. According to the response to TKIs, the patients were distributed into the optimal response, warning, and treatment failure groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14497DOI Listing

Keratosis pilaris-like eruption secondary to nilotinib in a child.

Pediatr Dermatol 2020 Jun 29. Epub 2020 Jun 29.

Department of Dermatology, University Hospital La Paz, Madrid, Spain.

Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14-year-old patient being treated with nilotinib who developed a keratosis pilaris-like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.14267DOI Listing

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.

Asian Pac J Cancer Prev 2020 Jun 1;21(6):1545-1550. Epub 2020 Jun 1.

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/ Dr Sardjito General Hospital, Yogyakarta, Indonesia.

The aim of this study was analyzing the BCR-ABL transcript types of patients with chronic myeloid leukemia (CML) in Dr Sardjito General Hospital, Yogyakarta, Indonesia. This study is very relevant because the data concerning BCR-ABL gene transcript types is very limited in Indonesia. Furthermore, it is important for patient's management, particularly in defining the tyrosine kinase inhibitors (TKIs) therapy and monitoring after therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2020.21.6.1545DOI Listing

ABO-Incompatible Kidney Transplantation After Bone Marrow Transplantation: A Case Report.

Transplant Proc 2020 Jun 22. Epub 2020 Jun 22.

Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Many studies have been made on ABO-compatible kidney transplants following hematopoietic stem cell transplantation. However, there have been few reports on ABO-incompatible kidney transplantation following hematopoietic stem cell transplantation (HSCT). We report on the case of a successful ABO-incompatible kidney transplantation with high titers after bone marrow transplantation experienced no infectious episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2020.01.173DOI Listing

Flow Cytometric Analysis of Monocytes and Granulocytes May Be Useful in the Distinction of Myeloid Neoplasms from Reactive Conditions: A Single Institution Experience and Literature Review.

Ann Clin Lab Sci 2020 May;50(3):327-332

Department of Pathology and Laboratory Medicine, The University of Kansas, Kansas City, KS, USA

Objective: To determine if the immunophenotype of monocytes and granulocytes could help differentiate between reactive conditions and myeloid neoplasms.

Materials: We analyzed 94 patients including acute myeloid leukemia (n=53), myelodysplastic syndrome (n=19), chronic myelomonocytic leukemia (n=13), and chronic myelogenous leukemia (n=9). Twenty-five cases of reactive condition were included as controls. Read More

View Article

Download full-text PDF

Source

Generalized granuloma annulare associated with essential thrombocythemia.

Clin Case Rep 2020 Jun 23;8(6):1065-1068. Epub 2020 Mar 23.

Good Health Clinic Tavernier Florida.

The only myeloproliferative neoplasm associated with generalized granuloma annulare (GA) is chronic myelogenous leukemia (CML). We present the first reported case of GA in a patient with essential thrombocythemia (ET). Future work investigating the shared pathophysiology of GA-associated CML and ET may improve our understanding of GA pathophysiology and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303850PMC

Chronic myelogenous leukemia presenting as central retinal vein occlusion.

Leuk Lymphoma 2020 Jun 22:1-4. Epub 2020 Jun 22.

Department of Medicine, Division of Hematology, Jewish General Hospital, McGill University, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1775203DOI Listing

Low-Density Lipoproteins, High-Density Lipoproteins (HDL), and HDL-Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability.

Lipids 2020 Jun 19. Epub 2020 Jun 19.

Department of Biology, Fairfield University, Fairfield, CT, 06824, USA.

Cellular lipid metabolism, lipoprotein interactions, and liver X receptor (LXR) activation have been implicated in the pathophysiology and treatment of cancer, although findings vary across cancer models and by lipoprotein profiles. In this study, we investigated the effects of human-derived low-density lipoproteins (LDL), high-density lipoproteins (HDL), and HDL-associated proteins apolipoprotein A1 (apoA1) and serum amyloid A (SAA) on markers of viability, cholesterol flux, and differentiation in K562 cells-a bone marrow-derived, stem-like erythroleukemia cell model of chronic myelogenous leukemia (CML). We further evaluated whether lipoprotein-mediated effects were altered by concomitant LXR activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lipd.12254DOI Listing

Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.

Int J Hematol 2020 Jun 18. Epub 2020 Jun 18.

Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan.

A 66-year-old man with hypertension was diagnosed with chronic myelogenous leukemia in 1996. Treatment was started with hydroxycarbamide and imatinib 400 mg in 1996 + 6, which was increased to 600 mg. Although he achieved a complete cytogenic response in 1996 + 9, he could not continue imatinib because of edema; the regimen was changed to nilotinib 800 mg in 1996 + 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02913-xDOI Listing

[MiR-124-3p Enhances the Sansitivity of Chronic Myelogenous Leukemia Cell K562-R to Imatinib by Targeting ABCA2].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Jun;28(3):789-796

Department of Internal Medicine Teaching and Research Section of Henan Medical College, Zhengzhou 451191, Henan Province, China,E-mail:

Objective: To investigate the effect and mechanism of miR-124-3p-targeing regulating ABCA2 on chronic myelogenous leukemia cell K562-R.

Methods: CML cells with miR-124-3p-overexpression and ABCA2-over-expression as well as subcutaneoustrans planted tumor nude mice were used as study objects. And the CML cells were divided into four groups: K562-R blank control, miR-124-3p mimic control, ABCA2-overexpression and mimic+PC ABCA2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.03.012DOI Listing

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.

J Hematol Oncol 2020 Jun 18;13(1):80. Epub 2020 Jun 18.

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inhibitors (TKIs) have shown a remarkable clinical activity in patients with CML, but their efficacy in treating Ph B-ALL is limited. Identifying additional therapeutic targets is important for the effective treatment of Ph B-ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00912-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302132PMC

Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome.

Case Rep Oncol 2020 May-Aug;13(2):569-577. Epub 2020 May 19.

Hamad Medical Corporation, Doha, Qatar.

Coronavirus disease-19 is a respiratory viral disease that commonly presents with mild symptoms. However, it can cause serious complications such as acute respiratory disease, especially in patients with comorbidities. As it is a new disease, the full picture of the disease and its complications are not yet fully understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275193PMC

Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice.

Expert Opin Drug Saf 2020 Jun 22:1-8. Epub 2020 Jun 22.

Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón , Madrid, Spain.

Objectives: Our objective was to analyze potential drug interactions (PDIs) between targeted OAAs and concomitant therapy in clinical practice.

Methods: A cross-sectional observational study was performed in cancer outpatients who started treatment with a targeted OAA between 1 December 2015 and 31 May 2019. PDIs were analyzed using the Lexicomp and the database About Herbs®. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2020.1781089DOI Listing

Pulmonary Complications of Bcr-Abl Tyrosine Kinase Inhibitors.

Eur Respir J 2020 Jun 11. Epub 2020 Jun 11.

INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, Le Plessis-Robinson, France

Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukemia. Following the success of imatinib, second and third generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.00279-2020DOI Listing

Quantum dots functionalized with 3-mercaptophenylboronic acids as novel nanoplatforms to evaluate sialic acid content on cell membranes.

Colloids Surf B Biointerfaces 2020 Sep 16;193:111142. Epub 2020 May 16.

Departamento de Biofísica e Radiobiologia, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, S/N, CB, UFPE, 50670-901, Recife, PE, Brazil. Electronic address:

Sialic acids (SAs) modulate essential physiological and pathological conditions, including cell-cell communication, immune response, neurological disorders, and cancer. Besides, SAs confer negative charges to cell membranes, also contributing to hemorheology. Phenylboronic acids, called as mimetic lectins, have been highlighted to study SA profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.colsurfb.2020.111142DOI Listing
September 2020

Increased basophils in peripheral blood: an underutilized criterion for the early diagnosis of chronic myelogenous leukemia.

Authors:
Antonio La Gioia

Scand J Clin Lab Invest 2020 Jun 11:1-2. Epub 2020 Jun 11.

Laboratory Medicine, Docemus, Torrevecchia Teatina, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365513.2020.1774799DOI Listing

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia.

Case Rep Oncol 2020 May-Aug;13(2):534-537. Epub 2020 May 13.

Medical Oncology, Augusta University, Augusta, Georgia, USA.

Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265745PMC

Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding.

Int J Mol Sci 2020 Jun 5;21(11). Epub 2020 Jun 5.

INSERM U935, University Paris Saclay, 94802 Villejuif, France.

Chronic myeloid leukemia (CML) is characterized by an inherent genetic instability, which contributes to the progression of the disease towards an accelerated phase (AP) and blast crisis (BC). Several cytogenetic and genomic alterations have been reported in the progression towards BC, but the precise molecular mechanisms of this event are undetermined. Transcription Factor 7 like 2 (TFC7L2) is a member of the TCF family of proteins that are known to activate WNT target genes such as Cyclin D1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21114057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312032PMC

Unilateral Macular Choroidal Neovascularization; a Rare Manifestation in Chronic Myelogenous Leukemia.

J Curr Ophthalmol 2020 Jan-Mar;32(1):103-106. Epub 2020 Mar 23.

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Purpose: To report a case of chronic myelogenous leukemia (CML) treatment with imatinib mesylate in the remission phase who developed unilateral macular choroidal neovascularization (CNV).

Methods: A 45-year-old male marketer with a 5-year history of CML treated with imatinib mesylate presented with 2 months history of progressive vision loss and metamorphopsia in the right eye.

Results: Fundus examination of the right eye revealed grey-white elevated retinal lesion with indistinct borders in the macula and retinal telangiectasia in the temporal macula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joco.2019.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265268PMC

Selective and sensitive detection of chronic myeloid leukemia using fluorogenic DNAzyme probes.

Anal Chim Acta 2020 Aug 30;1123:28-35. Epub 2020 Apr 30.

Research Center for Molecular Oncology and Functional Nucleic Acids, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, Henan Province, China. Electronic address:

One of the major challenges facing the early diagnosis of chronic myelogenous leukemia (CML) patients today is enhancing the simplicity, rapidness, sensitivity and specificity of detection assay for easy clinical implementation. RNA-cleaving fluorogenic DNAzymes (RFDs) are single-stranded DNA molecules with catalytic activity and can produce fluorescent signals when combined with specific targets. As K562 cells were the first established human immortalized myelogenous leukemia line, we try to screen several RFDs using the crude extracellular mixture of K562 cells through the SELEX process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aca.2020.04.069DOI Listing
August 2020
4.513 Impact Factor

Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia.

J Infect Chemother 2020 Jun 3. Epub 2020 Jun 3.

Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Tuberculous peritonitis is difficult to diagnose due to the disadvantages of ascitic culture and peritoneal biopsy. Although previous reports suggested that very high serum soluble interleukin-2 receptor (sIL-2R) levels may reflect the clinical activity of tuberculosis, little is known about the diagnostic utility of serum sIL-2R for tuberculous peritonitis. We describe a case of tuberculous peritonitis with chronic myelogenous leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jiac.2020.05.001DOI Listing

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.

Haematologica 2020 Jun 4. Epub 2020 Jun 4.

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2020.248187DOI Listing

Dual-modal label-free genosensor based on hemoglobin@gold nanocluster stabilized graphene nanosheets for the electrochemical detection of BCR/ABL fusion gene.

Talanta 2020 Sep 29;217:121093. Epub 2020 Apr 29.

Department of Chemistry, Amirkabir University of Technology, Tehran, Iran.

For the first time, we have successfully synthesized stable graphene nanosheets from graphite powder through sonication in the hemoglobin-capped gold nanoclusters (Hb@AuNCs) solution for biosensing application. This approach, as a simple method for the exfoliation and fragmentation of graphite in a nanocluster solution, enabled us to produce stable aqueous graphene dispersions at low cost and without the need for hazardous chemicals or tedious experimental procedures. In this method, Hb@AuNCs were used not only as stabilizing agent of graphene through non-covalent bonding, but also as dispersing agent of few-layer graphene nanosheets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.talanta.2020.121093DOI Listing
September 2020
3.545 Impact Factor

Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.

Cancers (Basel) 2020 May 29;12(6). Epub 2020 May 29.

School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

Chronic myelogenous leukemia (CML) is the most common type of leukemia in adults, and more than 90% of CML patients harbor the abnormal Philadelphia chromosome (Ph) that encodes the BCR-ABL oncoprotein. Although the ABL kinase inhibitor (imatinib) has proven to be very effective in achieving high remission rates and improving prognosis, up to 33% of CML patients still cannot achieve an optimal response. Here, we used CRISPR/Cas9 to specifically target the - junction region in K562 cells, resulting in the inhibition of cancer cell growth and oncogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061399DOI Listing

Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia.

Pharmacology 2020 Jun 2:1-9. Epub 2020 Jun 2.

Department of Medical Oncology/Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Background: Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual.

Summary: We reviewed case reports and series of 54 patients with chronic myeloid leukemia (CML) who developed autoimmune hemolysis between 1952 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507295DOI Listing

Hyperbaric Oxygen Therapy of an Adolescent Stem Cell Transplantation Recipient with Hemorrhagic Cystitis and BK Virus.

Case Rep Pulmonol 2020 13;2020:3465412. Epub 2020 May 13.

Department of Cardiopulmonary Sciences, School of Allied Health Professions, Loma Linda University, California, USA.

Hyperbaric oxygen therapy (HBOT) continues to show effectiveness in the treatment of several diseases and benefits such as fibroblast proliferation, capillary angiogenesis, and decreasing edema, especially in hemorrhagic cystitis (HC). We report a case of a 15-year-old male with chronic myelogenous leukemia status posthaploidentical stem cell transport with BK virus in the United States to be treated by HBOT. The patient received a total of 30 HBOT treatments for 90 minutes at 2 ATA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/3465412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243008PMC

Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells.

Turk J Pharm Sci 2020 Feb 19;17(1):49-55. Epub 2020 Feb 19.

Kumamoto University, School of Pharmacy, Department of Bioorganic Medicinal Chemistry, Kumamoto, Japan.

Objectives: Chronic myelogenous leukemia (CML) is a type of blood cancer that is initially treated with imatinib (first Abl kinase inhibitor). However, some patients with CML develop imatinib resistance. Several new generation drugs have been developed, but do not overcome this problem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjps.galenos.2018.49389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227864PMC
February 2020

Hyperleukocytosis, Artifactual Hypoglycemia, and Massive Hepato-Splenomegaly: A Case of Chronic Myelogenous Leukemia.

Am J Med Sci 2020 May 5. Epub 2020 May 5.

Department of Hematology-Oncology, St. Joseph's University Medical Center, Paterson, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2020.04.037DOI Listing

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.

Cancers (Basel) 2020 May 15;12(5). Epub 2020 May 15.

Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), University of Namur, 5000 Namur, Belgium.

Large randomized clinical trials and prior meta-analyses indicate that second-generation BCR-ABL tyrosine kinase inhibitors (TKIs) improve surrogate biomarkers in patients with chronic myeloid leukemia (CML) without providing survival benefits. The objective is to evaluate the long-term efficacy and the occurrence of vascular occlusion with second-generation BCR-ABL TKIs compared with imatinib in patients with CML. Three scientific databases, a clinical registry and abstracts from congress were searched to identify all randomized controlled trials that compared a second-generation BCR-ABL TKI to imatinib in patients with CML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281573PMC

Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin.

Genes (Basel) 2020 May 14;11(5). Epub 2020 May 14.

Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.

Treatments that include gemcitabine and carboplatin induce dose-limiting myelosuppression. The understanding of how human bone marrow is affected on a transcriptional level leading to the development of myelosuppression is required for the implementation of personalized treatments in the future. In this study, we treated human hematopoietic stem and progenitor cells (HSPCs) harvested from a patient with chronic myelogenous leukemia (CML) with gemcitabine/carboplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/genes11050549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288450PMC

Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.

Biol Blood Marrow Transplant 2020 May 16. Epub 2020 May 16.

Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain.

In this study, we compared the outcomes of patients with acute myelogenous leukemia (AML) in complete remission treated with myeloablative conditioning (MAC) and those treated with reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HCT). In addition, we explored the efficacy of dual T cell depletion using anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCy) for the prevention of graft-versus-host disease (GVHD) in patients undergoing RIC allo-HCT. Our study cohort comprised 356 adults with AML in complete remission who underwent allo-HCT between 2013 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.021DOI Listing

Role of crocin in several cancer cell lines: An updated review.

Iran J Basic Med Sci 2020 Jan;23(1):3-12

Department of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Cancer is a major public health problem worldwide. The most important considerable features of cancer cells are uncontrolled proliferation, up-regulated differentiation, and immortality. Crocin, as a bioactive compound of saffron and as a water-soluble carotenoid has radical scavenging, anti-hyperlipidemia, memory improving, and inhibition of tumor growth effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22038/IJBMS.2019.37821.8995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206843PMC
January 2020

Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.

Eur J Med Chem 2020 Jul 4;198:112331. Epub 2020 May 4.

Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Avenue, Moscow, 119991, Russian Federation; Fusion Pharma, Territory of the Skolkovo Innovation Center, 42 Bolshoi Bulvar Building 1, Moscow, 121205, Russian Federation. Electronic address:

The MDR1/P-glycoprotein (Pgp)/ABCB1 multidrug transporter is being investigated as a druggable target for antitumor therapy for decades. The natural product curcumin is known to provide an efficient scaffold for compounds capable of blocking Pgp mediated efflux and sensitization of multidrug resistant (MDR) cells to the Pgp transported drug doxorubicin (Dox). We performed molecular dynamics simulations and docking of curcumin derivatives into the Pgp model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2020.112331DOI Listing
July 2020
3.447 Impact Factor

Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions.

Leuk Lymphoma 2020 May 13:1-9. Epub 2020 May 13.

Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.

The Wilms' tumor 1 () gene is an important regulatory molecule that plays a vital role in cell growth and development. Initially, knowledge of was mostly limited to Wilms' tumor. Over the past years, numerous studies have shown that is aberrant expressed or mutated in hematopoietic malignancies, including acute leukemia (AL), myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1762884DOI Listing

[A case report of BCR-ABL negative chronic basophilic cell leukemia].

Zhonghua Xue Ye Xue Za Zhi 2019 07;40(7):613

Henan Provincial Key Laboratory of Hematopathology, Institute of Haematology, Henan Provincial People's Hospital, Zhengzhou 450002, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.018DOI Listing

[Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients].

Zhonghua Xue Ye Xue Za Zhi 2019 07;40(7):608-611

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.015DOI Listing

[The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia].

Zhonghua Xue Ye Xue Za Zhi 2019 Jul;40(7):578-583

Department of Hematology, Aerospace Central Hospital, Beijing 100049, China.

To investigate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of leukemia patients also suffering from central nervous system leukemia (CNSL) . A total of 48 leukemia patients with central nervous system leukemia admitted to our hospital from May 2012 to December 2017 were retrospectively analyzed. ① Including 22 cases of acute lymphocytic leukemia (ALL) , 21 cases of acute myeloid leukemia (AML) , and 5 cases of chronic myelogenous leukemia (CML) . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.008DOI Listing

[Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].

Zhonghua Xue Ye Xue Za Zhi 2019 Jul;40(7):547-553

Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.

To compare the clinical features between the 2 cohorts developing myelodysplastic syndrome or acute myeIogenous Ieukemia in Philadelphia chromosome-negative cells (Ph(-) MDS/AML) and maintaining disease stable in the patients with Philadelphia chromosome-positive chronic myeloid Ieukemia (Ph(+) CML) who had clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph(-)) during tyrosine kinase inhibtor (TKI) - therapy. We retrospectively analyzed Ph(+) CML patients who developed CCA/Ph(-) during TKI-therapy from May 2001 to December 2017. Data of CCA/Ph(-) 63 patients, including 7 progressing to Ph(-) MDS/AML and 56 remaining disease stable were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.003DOI Listing

BCR-ABL Tyrosine Kinase Inhibitors Promote Pathological Changes in Dilator Phenotype in the Human Microvasculature.

Microcirculation 2020 May 12. Epub 2020 May 12.

Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States.

Objective: Treatment with BCR-ABL tyrosine kinase inhibitors (TKIs) is the standard of care for patients with chronic myeloid leukemia, however evidence indicates these compounds may have cardiovascular side-effects. This study sought to determine if ex vivo exposure of human adipose arterioles to the BCR-ABL TKIs imatinib and nilotinib causes endothelial dysfunction.

Methods: Human adipose arterioles were incubated overnight in cell culture media containing vehicle (PBS), imatinib (10 µM) or nilotinib (100 µM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/micc.12625DOI Listing

A case of long-term dasatinib-induced proteinuria and glomerular injury.

CEN Case Rep 2020 May 9. Epub 2020 May 9.

Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma, 371-8511, Japan.

A 52-year-old woman was diagnosed with chronic myeloid leukemia. Treatment with dasatinib, a second-generation Bcr-Abl tyrosine kinase inhibitor, was initiated, and complete cytogenetic remission was achieved. Two years later, proteinuria occurred, and the urinary protein level increased gradually in the next 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13730-020-00484-8DOI Listing

Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells.

Gene 2020 Aug 5;750:144723. Epub 2020 May 5.

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia. Electronic address:

The BCL2L12, one of the latest discovered members of the BCL2 family, has both pro- and anti-apoptotic roles that are cell-type-dependent. Its role in tumorigenesis is highly implicated. Sixty-three splice variants of this gene have been identified so far, with significant differences in expression patterns between various cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2020.144723DOI Listing